Ellen Xia - Concepedia

Concepedia

Author

Ellen Xia

Merck & Co., Inc., Rahway, NJ, USA (United States)ORCID

Also Known As

E XIA, E. Xia, Ellen Xia, Enzhu Xia, Erjie Xia

24

Publications

1.3K

Citations

15

H-Index

29

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)WuXi AppTec (China)United States Military Academy LabCorp (United States)Institute of Virology of the Slovak Academy of Sciences

EX

About

Ellen Xia is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, drug discovery, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	14	638
2	Natural Sciences	7	7	540
3	Biomolecular Engineering	6	6	244
4	Biochemistry	3	3	77
5	Engineering	1	1	16

Ellen Xia

×

18

Publications

1.3K

Citations

15

H-Index

	Year	Citations
Selective small-molecule inhibition of an RNA structural element John A. Howe, Hao Wang, Thierry Fischmann, Nature Natural SciencesRna Structure PredictionSelective Small-molecule InhibitionRna BiologyMolecular Biology	2015	411
SCH 503034, a Mechanism-Based Inhibitor of Hepatitis C Virus NS3 Protease, Suppresses Polyprotein Maturation and Enhances the Antiviral Activity of Alpha Interferon in Replicon Cells Bruce A. Malcolm, R. Liu, Frederick Lahser, Antimicrobial Agents and Chemotherapy Viral ReplicationHepatitis C VirusImmunologyMolecular BiologyHcv Replication	2006	316
Characterization of resistance mutations against HCV ketoamide protease inhibitors Xinchun Tong, Stéphane Bogen, Robert A. Chase, Antiviral Research Drug DiscoveryResistance Mutation (Virology)Resistance MutationsBiomolecular EngineeringDrug Resistance	2008	127
The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons Frederick Lahser, Karin Bystol, Stephanie Curry, Antimicrobial Agents and Chemotherapy Hcv Ns5a InhibitorGeneticsImmunologyHcv Rna ReductionHcv Rna Replication	2016	57
Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms Ling Tong, Wensheng Yu, Lei Chen, Journal of Medicinal Chemistry Medicinal ChemistryAntiviral CompoundMolecular VirologyMedicineOptimized Activity	2016	47
Preclinical Characterization of the Antiviral Activity of SCH 900518 (Narlaprevir), a Novel Mechanism-Based Inhibitor of Hepatitis C Virus NS3 Protease Xiao Tong, Ashok Arasappan, Frank Bennett, Antimicrobial Agents and Chemotherapy ImmunologySch 900518Novel Mechanism-based InhibitorAntiviral DrugSmall Molecules	2010	46
Impact of Naturally Occurring Variants of HCV Protease on the Binding of Different Classes of Protease Inhibitors Xiao Tong, Zhuyan Guo, Jacquelyn Wright-Minogue, Biochemistry	2006	43
Identification of HCV protease inhibitor resistance mutations by selection pressure-based method Ping Qiu, Vincent J Sanfiorenzo, Stephanie Curry, Nucleic Acids Research	2009	42
Discovery of silyl proline containing HCV NS5A inhibitors with pan-genotype activity: SAR development Anilkumar G. Nair, Qingbei Zeng, Oleg Selyutin, Bioorganic & Medicinal Chemistry Letters Sar DevelopmentSilyl ProlineMedicineImmunologyAntiviral Drug Development	2016	27
A novel HCV NS3 protease mutation selected by combination treatment of the protease inhibitor boceprevir and NS5B polymerase inhibitors Robert A. Chase, Angela Skelton, Ellen Xia, Antiviral Research Molecular VirologyPathogenesisImmunologyAntiviral Drug DevelopmentProtease Inhibitor Boceprevir	2009	19

Page 1